Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to addressing one of the most prevalent neurological disorders worldwide. Organon and Eli Lilly Expand Emgality Agreement Organon, a global healthcare company with a focus on women’s health, and Eli Lilly […]
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy for adults. The approval marks a significant milestone for Lilly, as Emgality becomes available as a once-monthly, self-administered, subcutaneous injection designed to help prevent migraines. Emgality, a calcitonin gene-related peptide […]
